Why Nexstellis quietly stands out in Organon & Co’s contraception portfolio

Nexstellis is Organon & Co’s modern pill for women who want reliable contraception with a different hormone profile and a clearer focus on everyday tolerability. What the tablet can do, where it convinces, and where women still need to look closely.

Reviewed: ad hoc news Accessory & Components desk. Edited and checked on 2026-06-17, 09:47. Details in the imprint.

Nexstellis from Organon & Co is one of those small, pale tablets that promises a lot in everyday life - safe contraception, a gentler hormone profile, and fewer nagging side effects when everything goes well. You swallow it with a sip of water, but the idea behind it is bold. A new estrogen, drospirenone as the progestin, and a clear pitch to women who have had enough of the “same old pill”.

What makes Nexstellis different

The first thing that stands out with Nexstellis is the estrogen. Instead of the long-established ethinyl estradiol, the pill combines drospirenone with estetrol, a so-called native estrogen derived from a plant-based source and structurally identical to a hormone produced during pregnancy. The official US prescribing information describes estetrol as a selective estrogen with a distinct profile. In theory, this should offer effective contraception with a different impact on the liver and clotting factors compared with older pills.

Organon acquired global rights to commercialize Nexstellis in many markets from Belgian specialist Mithra, making the product a kind of co-production between pharma mid-cap and women’s health pure play. Mithra highlights that Nexstellis (marketed as Estelle in some regions) is the first combined oral contraceptive based on estetrol. That gives Organon something it can advertise as genuinely new in a very crowded pill market.

Daily use and how it feels

In everyday life, Nexstellis behaves like a classic modern pill. One blister, 24 active tablets and 4 placebo tablets, one pill per day at roughly the same time. For users this means a familiar rhythm - hardly any learning curve, just a new name on the box and a slightly different hormone combination inside. The US approval announcement underscores the once-daily schedule and fixed dosing.

Women who switch often describe it as unspectacular in the best sense: you take the tablet, you get on with work, study, or family life. The promise Organon is pitching is less about dramatic visible effects and more about the quieter aspects - how stable the cycle feels, how the skin behaves, how the mood holds up over the month.

Strengths, but also limits

Clinical trials showed Nexstellis reached typical modern pill efficacy, with Pearl Index values comparable to established combined oral contraceptives in women up to 35 years. The company’s data package emphasizes a consistent safety profile, especially regarding body weight and blood pressure over the study period.

Still, Nexstellis remains a hormonal contraceptive with all associated caveats. Women with a history of thrombosis, certain cardiovascular disorders, or migraine with aura usually need different options. And as with any pill, spotting, breast tenderness, or mood changes can appear, especially in the first months, before things settle or the gynecologist advises a switch.

Market positioning and availability

Nexstellis is currently positioned primarily in the US and selected international markets, often via specialist gynecologists and women’s health clinics rather than supermarket-style broad distribution. That fits Organon’s strategy of focusing on higher-value prescription products rather than chasing every generic competitor down the price ladder.

Pricing sits in the branded segment. In many cases, insurance coverage or national reimbursement schemes determine whether women experience the pill as affordable or as a small monthly luxury. In countries where Estelle is the brand name, regional partners support Organon with local marketing and distribution, tailoring the message to different healthcare systems.

Where it fits in Organon’s portfolio

Within Organon & Co’s broader women’s health lineup, Nexstellis complements long-acting contraceptives and fertility-related therapies. The idea is a rounded offering that covers different life stages - from the first contraception decision in the early twenties through family planning and later menopause care.

Strategically, Nexstellis gives Organon a branded asset in an area that regulators, doctors, and patients know extremely well. That can be both blessing and curse: expectations are high, and new safety data are monitored closely. But if the pill continues to perform steadily in real-world use, it supports the narrative of Organon as a specialist rather than a generalist.

Company context and stock reference

Organon & Co emerged from Merck as a company explicitly focused on women’s health, biosimilars, and established medicines, and Nexstellis fits neatly into that core story. For investors, it is one of several branded growth drivers in a portfolio that also contains many mature products with more predictable cash flows. Shares of Organon & Co (US68622V1061) trade on the New York Stock Exchange in US dollars.

Nexstellis at a glance

• Product: Nexstellis
• Manufacturer: Organon & Co.
• Category: Accessory/Spare part - prescription oral contraceptive
• Launch: First FDA approval in 2021, subsequent roll-out in additional markets
• RRP / Price: Branded pricing in the US, often subject to insurance coverage and co-pay programs
• Availability: Prescription-only via gynecologists and pharmacies in the US and selected international markets
• Target group: Women of reproductive age seeking hormonal contraception with a different estrogen profile
• Highlight / USP: First combined oral contraceptive using estetrol with drospirenone, pitched for effective birth control and a distinct hormonal profile

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.